CompletedPhase 2NCT00720356
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Northwestern University
- Principal Investigator
- Jeffrey J. Raizer, MD, MDRobert H. Lurie Cancer Center
- Intervention
- bevacizumab(drug)
- Enrollment
- 115 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2018
Study locations (9)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States
- Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
- Evanston Hospital, Evanston, Illinois, United States
- Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
- Neuro-Oncology Associates at Baylor University Medical Center, Dallas, Dallas, Texas, United States
- M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
- The Methodist Hospital Neurological Institute, Houston, Texas, United States
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
M.D. Anderson Cancer Center
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00720356 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05363826Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC